2025年全球可吸入生技藥品市場報告

預計未來幾年可吸入生技藥品市場規模將快速成長；到2029年，其規模將成長至59億美元，複合年成長率為16.0%。預測期內的成長可歸因於全球老齡化人口的不斷成長、新興市場醫療基礎設施的不斷擴張、對生技藥品治療的監管支持力度的不斷加大以及傳染性呼吸道疾病病例的不斷增加。預計這段時期的主要趨勢包括藥物傳輸系統的進步、智慧吸入器技術的整合、氣霧劑科學的創新、生物製藥的發展以及奈米顆粒載體的進步。

預計未來幾年，呼吸系統疾病的日益普及將顯著促進可吸入生技藥品市場的成長。呼吸系統疾病包括影響肺部和呼吸系統其他組成部分（包括氣道、鼻腔和肺）的疾病和病症。這些疾病的增加主要是由於空氣污染的加劇，空氣污染使人們暴露於有害顆粒物和污染物中，加劇了氣喘、慢性阻塞性肺病(COPD) 和肺癌等疾病。可吸入生技藥品對這些疾病尤其有效，因為它們可以將標靶治療直接作用於肺部，減少發炎並改善肺功能，同時限制全身副作用。例如，2024 年 6 月，澳洲政府機構澳洲健康與福利研究所報告稱，到 2023 年，COPD 將佔總疾病負擔的 3.6%，佔呼吸系統疾病負擔的 50%。因此，呼吸系統疾病的增加正在顯著推動可吸入生技藥品市場的發展。

吸入式生技藥品市場的主要企業正專注於開發吸入式胰島素等突破性解決方案，以提高患者的依從性並提供更快的血糖控制。吸入式胰島素是透過吸入將胰島素直接輸送到肺部血液中，而不是透過注射或胰島素幫浦。在這種方法中，粉狀或氣霧化的胰島素被吸入並從肺部吸收，迅速進入血液並調節血糖值。例如，2025年2月，印度製藥公司Cipla Limited獲得了中央藥品標準控制組織對世界上最快的吸入式胰島素Afrezza的監管批准，該藥物為患有1型和2型糖尿病的成年人提供了無針核准。這種超速效胰島素在吸入後12-15分鐘內開始起效，並且非常接近模擬胰島素對餐後的自然反應，從而改善血糖控制。吸入式胰島素為每日注射提供了更舒適的替代方案，特別是對於那些對注射感到焦慮的患者，並提高了對胰島素治療的依從性。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場 - 宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

• 全球可吸入生技藥品PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
• 最終用途產業分析
• 全球可吸入生技藥品市場：成長率分析
• 全球吸入式生技藥品市場表現：規模與成長，2019-2024
• 全球可吸入生技藥品市場預測：2024-2029 年、2034 年規模與成長
• 可吸入生技藥品的全球總目標市場（TAM）

第6章市場區隔

• 全球可吸入生技藥品市場類型、績效及預測（2019-2024、2024-2029、2034）
• 胜肽和蛋白質
• 疫苗
• 單株抗體
• 基於RNAi的治療方法
• 其他類型
• 全球吸入性生技藥品市場（依劑型分類）：歷史資料及預測（2019-2024 年、2024-2029 年、2034 年）
• 乾粉吸入器
• 定量噴霧吸入器
• 噴霧器
• 其他劑型
• 全球可吸入生技藥品市場（依通路）：歷史資料及預測（2019-2024 年、2024-2029 年、2034 年）
• 醫院藥房
• 零售藥局
• 網路藥局
• 全球可吸入生技藥品市場的應用、績效及預測（2019-2024、2024-2029、2034）
• 呼吸系統疾病
• 糖尿病
• 癌症
• 其他用途
• 全球可吸入生技藥品市場，依胜肽及蛋白質類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 胰島素
• 生長激素
• 酵素替代療法
• 其他胜肽和蛋白質
• 全球吸入式生技藥品市場，依疫苗類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 流感疫苗
• 其他呼吸道疫苗
• 全球吸入式生技藥品市場，依單株抗體類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 呼吸道單株抗體
• 免疫調節單株抗體
• 其他單株抗體
• 全球可吸入生技藥品市場，依基於 RNAi 的治療類型細分，績效及預測，2019-2024 年、2024-2029 年、2034 年
• 基於RNA的呼吸系統疾病藥物
• 其他基於RNAi的治療方法
• 全球可吸入生技藥品市場及其他細分市場，依類型、實際及預測，2019-2024 年、2024-2029 年、2034 年
• 基因治療
• 吸入小分子
• 其他創新吸入生技藥品

第7章 區域和國家分析

• 全球可吸入生技藥品市場各地區、表現及預測（2019-2024、2024-2029、2034）
• 全球可吸入生技藥品市場（依國家/地區分類）、績效及預測（2019-2024 年、2024-2029 年、2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章 澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章 德國市場

第18章 法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章競爭格局與公司概況

• 可吸入生技藥品市場：競爭格局
• 可吸入生技藥品市場：公司簡介
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型創新企業

• Medtronic PLC
• Moderna Inc.
• Pfizer Inc. and BioNTech SE
• Teva Pharmaceuticals
• Baxter International
• Lonza Group AG
• CanSino Biologics Inc.
• Cipla Ltd.
• Insmed Incorporated
• Kamada Pharmaceuticals
• Vectura Group plc
• F. Hoffmann-La Roche Ltd
• Iconovo AB
• Synairgen plc
• Ab Initio Pharma LLC

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章 高市場潛力國家、細分市場與策略

• 2029年可吸入生技藥品市場：提供新機會的國家
• 2029年可吸入生技藥品市場：細分市場帶來新機會
• 可吸入生技藥品2029年：成長策略
  • 基於市場趨勢的策略
  • 競爭對手的策略

第36章 附錄

Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.

The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.

Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.

In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma's expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.

Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
• 2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
• Subsegments:
• 1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
• 2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
• 3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
• 4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
• 5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
• Companies Mentioned: Bayer AG; Sanofi SA; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhalable Biologics Market Characteristics

3. Inhalable Biologics Market Trends And Strategies

4. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inhalable Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inhalable Biologics Market Growth Rate Analysis
• 5.4. Global Inhalable Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inhalable Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inhalable Biologics Total Addressable Market (TAM)

6. Inhalable Biologics Market Segmentation

• 6.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptides And Proteins
• Vaccines
• Monoclonal Antibodies
• RNAi-Based Therapeutics
• Other Types
• 6.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
• Other Dosage Forms
• 6.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Diseases
• Diabetes
• Cancer
• Other Applications
• 6.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin
• Growth Hormones
• Enzyme Replacement Therapies
• Other Peptides And Proteins
• 6.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza Vaccines
• Other Respiratory Vaccines
• 6.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Monoclonal Antibodies
• Immunomodulatory Monoclonal Antibodies
• Other Monoclonal Antibodies
• 6.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA-Based Drugs For Respiratory Diseases
• Other RNAi-Based Therapeutics
• 6.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapies
• Small Molecule Inhalable Drugs
• Other Innovative Inhalable Biologics

7. Inhalable Biologics Market Regional And Country Analysis

• 7.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhalable Biologics Market

• 8.1. Asia-Pacific Inhalable Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhalable Biologics Market

• 9.1. China Inhalable Biologics Market Overview
• 9.2. China Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhalable Biologics Market

• 10.1. India Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhalable Biologics Market

• 11.1. Japan Inhalable Biologics Market Overview
• 11.2. Japan Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhalable Biologics Market

• 12.1. Australia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhalable Biologics Market

• 13.1. Indonesia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhalable Biologics Market

• 14.1. South Korea Inhalable Biologics Market Overview
• 14.2. South Korea Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhalable Biologics Market

• 15.1. Western Europe Inhalable Biologics Market Overview
• 15.2. Western Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhalable Biologics Market

• 16.1. UK Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhalable Biologics Market

• 17.1. Germany Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhalable Biologics Market

• 18.1. France Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhalable Biologics Market

• 19.1. Italy Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhalable Biologics Market

• 20.1. Spain Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhalable Biologics Market

• 21.1. Eastern Europe Inhalable Biologics Market Overview
• 21.2. Eastern Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhalable Biologics Market

• 22.1. Russia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhalable Biologics Market

• 23.1. North America Inhalable Biologics Market Overview
• 23.2. North America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhalable Biologics Market

• 24.1. USA Inhalable Biologics Market Overview
• 24.2. USA Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhalable Biologics Market

• 25.1. Canada Inhalable Biologics Market Overview
• 25.2. Canada Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhalable Biologics Market

• 26.1. South America Inhalable Biologics Market Overview
• 26.2. South America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhalable Biologics Market

• 27.1. Brazil Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhalable Biologics Market

• 28.1. Middle East Inhalable Biologics Market Overview
• 28.2. Middle East Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhalable Biologics Market

• 29.1. Africa Inhalable Biologics Market Overview
• 29.2. Africa Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhalable Biologics Market Competitive Landscape And Company Profiles

• 30.1. Inhalable Biologics Market Competitive Landscape
• 30.2. Inhalable Biologics Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Inhalable Biologics Market Other Major And Innovative Companies

• 31.1. Medtronic PLC
• 31.2. Moderna Inc.
• 31.3. Pfizer Inc. and BioNTech SE
• 31.4. Teva Pharmaceuticals
• 31.5. Baxter International
• 31.6. Lonza Group AG
• 31.7. CanSino Biologics Inc.
• 31.8. Cipla Ltd.
• 31.9. Insmed Incorporated
• 31.10. Kamada Pharmaceuticals
• 31.11. Vectura Group plc
• 31.12. F. Hoffmann-La Roche Ltd
• 31.13. Iconovo AB
• 31.14. Synairgen plc
• 31.15. Ab Initio Pharma LLC

32. Global Inhalable Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhalable Biologics Market

34. Recent Developments In The Inhalable Biologics Market

35. Inhalable Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Inhalable Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inhalable Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inhalable Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer